CRISPR Therapeutics
CRSP NASDAQ
Medicare add-on payments
- New
- 0
- Continued
- 1
- Lost
- 0
| Status | Technology | Max add-on payment | Implied cost per case |
|---|---|---|---|
| Continued | CASGEVY (exagamglogene autotemcel); Sickle Cell Disease indication | $1,650,000 | $2,200,000 |
FDA device recalls, last 36 months
FDA data as of . Source: openFDA. FDA data may be out of date.
MediDash tracks device recalls only. No device recalls are matched to this company.